Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) was a randomized controlled trial which recruited 4420 patients in the United Kingdom who were newly diagnosed with symptomatic or non-secretory multiple myeloma to study the use of thalidomide, bortezomib, lenalidomide, carfilzomib and vorinostat in their initial treatment plans.

This dataset contains 962 paired samples (cancerous and normal) from 463 patients in the Myeloma XI trial. DNA was extracted from CD138+ cells from whole bone marrow and peripheral white blood cells. Whole exome sequencing and targeted capture of the IGH/K/L and MYC loci were performed to analyze and detect somatic mutations.